Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus CYCRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus CYCRIN.
AYGESTIN vs CYCRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, suppressing ovulation and inducing a withdrawal bleeding in an estrogen-primed endometrium. It exerts its effects via binding to progesterone receptors, leading to endometrial transformation and inhibition of endometrial proliferation.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
2.5 mg to 10 mg orally once daily for 5 to 10 days per cycle.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Terminal elimination half-life ranges from 12 to 24 hours, supporting once-daily dosing for continuous hormone replacement.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Primarily renal (50-60% as sulfate and glucuronide conjugates), with approximately 30% fecal elimination.
Category C
Category C
Progestin
Progestin